Skip to main content
. 2013 Jun;182(6):2071–2081. doi: 10.1016/j.ajpath.2013.02.029

Figure 4.

Figure 4

Anti–IL-17A treatment after acute disease improves motor task performance. A: Inverted screen performance. The EAE+anti–IL-17A group remained on the inverted screen for longer before a double hindlimb footfall and remained on the screen for longer than IgG-treated animals on PSDs 37 and 41. B: Rotarod performance. EAE+anti–IL-17A–treated animals also displayed an improvement on PSDs 37 and 41. Note that both groups were comparable during the acute phase of disease (PSDs 13, 16, and 20) compared with CFA controls. Data are shown as means ± SEM. n = 25 in the EAE+anti–IL-17A group, n = 24 in the EAE+IgG group; n = 12 in the CFA group. ∗P < 0.05 EAE+anti–IL-17A versus EAE+IgG.